---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013543"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-19T23:50:36.945726+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Glucotrack to present first-in-human CBGM data at ADA 85th Scientific Sessions

## Summary
- Will present safety & performance data from first-in-human trial of implantable continuous blood glucose monitor (CBGM).
- Live presentation by CSO Mark Tapsak on June 21 in Innovation Hub; poster session June 22.
- CBGM measures glucose directly from blood, lasts up to 3 years, no on-body wearable.
- Company preparing for next clinical phase (long-term feasibility study).

## SEC filing metadata
- accession: 0001641172-25-013543
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000164117225013543/0001641172-25-013543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000164117225013543/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013543
- JSON: https://secwatch.observer/filing/0001641172-25-013543.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.